Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2025)

Historic FCF Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 127.77%.

  • ARS Pharmaceuticals' FCF Margin rose 5785700.0% to 127.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.25%, marking a year-over-year increase of 17322400.0%. This contributed to the annual value of 14.57% for FY2024, which is 1981512300.0% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' FCF Margin is 127.77%, which was up 5785700.0% from 288.61% recorded in Q2 2025.
  • ARS Pharmaceuticals' FCF Margin's 5-year high stood at 48.17% during Q4 2024, with a 5-year trough of 166990.0% in Q2 2023.
  • In the last 4 years, ARS Pharmaceuticals' FCF Margin had a median value of 1047.66% in 2022 and averaged 21702.52%.
  • Per our database at Business Quant, ARS Pharmaceuticals' FCF Margin tumbled by -1654822400bps in 2023 and then soared by 1655266000bps in 2024.
  • ARS Pharmaceuticals' FCF Margin (Quarter) stood at 3022.22% in 2022, then crashed by -5425bps to 166990.0% in 2023, then skyrocketed by 100bps to 48.17% in 2024, then crashed by -365bps to 127.77% in 2025.
  • Its FCF Margin was 127.77% in Q3 2025, compared to 288.61% in Q2 2025 and 512.14% in Q1 2025.